secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001615219-24-000055
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharmaceuticals announces FDA partial clinical hold on seclidemstat trial after grade 4 adverse event
--------------------------------------------------------------------------------

- A patient in MDACC's trial of seclidemstat + azacitidine for MDS/CMML experienced a serious unexpected grade 4 adverse event.
- FDA placed partial clinical hold; no new patients may enroll, but current subjects benefiting may continue treatment.
- Salarius will support MDACC in analyzing data and responding to FDA questions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/0001615219-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/flks-20240709.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer